Data from Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung Cancer
Takahiko Murayama(Kanazawa University), Israel Cañadas(Fox Chase Cancer Center), Catherine B. Meador(Vanderbilt University Medical Center), Tetsuo Tani(Keio University), Xueying Ma(Fox Chase Cancer Center), Yin P. Hung(Harvard University), Cloud P. Paweletz(Massachusetts General Hospital), Tran C. Thai(Dana-Farber Cancer Institute), Jun Nakayama(Osaka International Cancer Institute), David A. Barbie(Dana-Farber Cancer Institute), Elena V. Ivanova(Massachusetts General Hospital), William Kim(University of San Diego), Kathy Q. Cai(Fox Chase Cancer Center), Navin R. Mahadevan(Brigham and Women's Hospital), Aaron N. Hata(Harvard University), Erik H. Knelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yuqiao Pan(Fox Chase Cancer Center), Hideo Watanabe(St. Catherine University)
Cited by 0
Related Papers
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k